Swiss Building Stock News

Earnings setback and dividend affirmation come into focus Swatch Group (SWX:UHR) is in the spotlight after full year 2025 results showed sales of CHF 6,280 million and net income of CHF 3 million, alongside confirmation of an annual dividend of CHF 4.50 per share. See our latest analysis for Swatch Group. The annual results and dividend affirmation arrived alongside strong near term momentum, with a 1 day share price return of 2.43% and a 30 day share price return of 12.53%. However, the 3...

If you are wondering whether Novartis shares still offer value at around CHF 121.00, it helps to step back and look at what the current price actually implies about the company. The stock has shown solid momentum recently, with returns of 3.5% over 7 days, 6.1% over 30 days, 11.5% year to date, 27.8% over 1 year, 77.8% over 3 years and 89.7% over 5 years. Recent news flow around Novartis has focused on its position as a large pharma name and ongoing interest in its pipeline and portfolio...

As optimism about the eurozone economy continues to bolster investor sentiment, European markets have been experiencing a period of resilience despite recent volatility. In this environment, stocks with high insider ownership can be particularly appealing to investors, as they often suggest confidence from those closest to the company in its growth potential and strategic direction.

Vanguard founder Jack Bogle helped spearhead the low-cost index fund, putting average returns within reach of every...

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...

As the pan-European STOXX Europe 600 Index reaches new intraday highs, optimism about the eurozone economy is helping to counteract recent market volatility. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities that may offer potential value as the broader market sentiment remains buoyant.

As optimism about the eurozone economy helps counteract recent market volatility, European markets have shown resilience with key indices like the STOXX Europe 600 Index reaching new highs. In this environment, growth companies with high insider ownership are particularly intriguing as they may signal confidence from those closest to the business, making them noteworthy in today's investment landscape.

Key Insights Significant control over Avolta by retail investors implies that the general public has more power to...

Why the SCD53 CO2 sensor launch matters for Sensirion Holding (SWX:SENS) Sensirion Holding (SWX:SENS) has drawn fresh attention after announcing its SCD53 CO2 sensor, designed for long term accuracy without regular manual recalibration or outdoor air exposure in demanding applications. See our latest analysis for Sensirion Holding. That SCD53 launch lands at a time when Sensirion Holding’s 1 day share price return of 2.50% and 7 day share price return of 1.59% sit alongside a 30 day share...

Luzerner Kantonalbank (SWX:LUKN) recently announced an annual dividend of CHF 1.35 per share, payable on April 20, 2026, with the ex-dividend date on April 16 and the record date on April 17. See our latest analysis for Luzerner Kantonalbank. Beyond the upcoming dividend, Luzerner Kantonalbank’s share price has been firming, with a 30 day share price return of 7.3% and a 90 day gain of 16.0%, while the 1 year total shareholder return of 49.4% points to momentum that has built over time. If...

Stadler Rail AG's ( VTX:SRAIL ) price-to-earnings (or "P/E") ratio of 68x might make it look like a strong sell right...

Galderma Group (SWX:GALD) is back in focus after the U.S. FDA accepted its BLA resubmission for RelabotulinumtoxinA, a neuromodulator targeting adult frown lines and crow's feet in the aesthetics market. See our latest analysis for Galderma Group. The FDA update follows a mixed price pattern, with a 1-day share price return of 1.84% and a 7-day share price return of 1.63%, offset by a 30-day share price return decline of 9.56% and a year-to-date share price return decline of 6.68%. The 1-year...

Fresh equity placement puts Cosmo Pharmaceuticals in focus Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after completing a private placement of 937,086 treasury shares, equal to 5.3% of its outstanding shares, with participation from Small Cap World Fund of the Capital Group. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF117.0, Cosmo Pharmaceuticals has seen a 30 day share price return of 7.93% and a 90 day gain of 80.28%. Its 1 year total shareholder...

Amidst recent market volatility, European indices like the STOXX Europe 600 have shown resilience, buoyed by optimism surrounding the eurozone economy. As investors navigate this landscape, growth companies with high insider ownership often attract attention due to their potential alignment of interests between management and shareholders, a factor that can be particularly appealing in times of economic uncertainty.

There wouldn't be many who think Jungfraubahn Holding AG's ( VTX:JFN ) price-to-earnings (or "P/E") ratio of 22.7x is...

Why this new SMA launch matters for Partners Group Holding (SWX:PGHN) BlackRock and Partners Group Holding (SWX:PGHN) have introduced a multi alternatives separately managed account solution that packages private equity, private credit, and real assets access for financial advisors in a single, streamlined offering. See our latest analysis for Partners Group Holding. The new SMA launch comes after a weaker recent stretch for the shares, with a 7 day share price return showing a 6.49% decline...

INFICON guidance and what it might mean for shareholders INFICON Holding (SWX:IFCN) has drawn investor focus after issuing preliminary 2025 guidance that points to sales of about US$673.7 million and operating income of roughly US$112.3 million, compared with US$671.0 million and US$136.0 million in the prior year. See our latest analysis for INFICON Holding. The preliminary 2025 guidance, which points to broadly steady sales and lower operating income, lands after a strong 30-day share price...

If you have been wondering whether Roche Holding's current share price really lines up with its underlying worth, this article walks you through the key numbers that matter. Over the short term the stock has been relatively steady, with a 0.2% decline over the last 7 days. The 30 day, year to date and 1 year returns sit at 3.8%, 8.7% and 25.8% respectively, and the 3 year and 5 year figures are 41.4% and 33.3%. Recent coverage of Roche has focused on its position as a global healthcare group...

Executive reshuffle puts leadership focus back on core functions Flughafen Zürich (SWX:FHZN) has kicked off a broad management reshuffle, cutting its Executive Board from seven to six members and confirming the planned exit of Chief People & Communication Officer Manuela Staub in July 2026. See our latest analysis for Flughafen Zürich. At a share price of CHF249.6, Flughafen Zürich has seen a 4.44% 7 day share price return but a 4.22% 30 day share price decline. Its 1 year total shareholder...

The Swatch Group AG recently reported full-year 2025 results, with sales of CHF 6,280 million and net income of CHF 3 million, and affirmed an annual dividend of CHF 4.50 per share payable on May 19, 2026. The decision to maintain the dividend despite much weaker profitability offers a clear signal about management’s confidence in the group’s financial resilience and priorities for rewarding shareholders. We will now examine how the earnings weakness paired with the affirmed dividend shapes...

Why lucerastat’s new Phase 3 plan matters for Idorsia shareholders Idorsia (SWX:IDIA) has agreed with the US FDA on a Phase 3 registration program for lucerastat in Fabry disease, centered on kidney outcomes and backed by recently published MODIFY trial data. For you as an investor, this means lucerastat is moving from exploratory late stage data into a clearly defined path that is intended to support a potential marketing application, with health authority alignment already in place. See our...

Julius Bär Gruppe (SWX:BAER) has released its full year 2025 results, reporting net income of CHF 763.7 million and earnings per share lower than the prior year, a key focus for investors. See our latest analysis for Julius Bär Gruppe. At a share price of CHF66.82, Julius Bär Gruppe has delivered a 22.92% 90 day share price return and a 23.34% 1 year total shareholder return, suggesting momentum has been building even as earnings softened and the board proposed an unchanged CHF2.60 dividend...

Why Valiant Holding’s latest dividend and earnings matter Valiant Holding (SWX:VATN) has drawn fresh attention after reporting its 2025 full year results, alongside an annual dividend of CHF 6.00 per share. This gives investors clearer visibility on income and recent profitability. See our latest analysis for Valiant Holding. The earnings announcement and CHF 6.00 dividend appear to have been well received, with the share price at CHF 159.60 and a 90 day share price return of 19.64%,...

Earnings, dividend proposal and operating metrics at a glance Swiss Prime Site (SWX:SPSN) has paired its full year 2025 earnings release with a proposed dividend increase and fresh data on portfolio vacancy, acquisitions and asset management inflows, giving investors several angles to reassess the stock. For 2025, the company reported sales of CHF 456.81 million compared with CHF 463.50 million a year earlier. Net income came in at CHF 382.47 million versus CHF 360.25 million, while basic...